India’s drug regulator has begun drafting new guidelines for high-risk solvents used in children’s medicines, after deaths tied to contaminated cough syrups. Investigators reportedly found the solvents can carry toxic impurities. The regulator is consulting pharmaceutical companies to review current solvent practices and push safer alternatives, a move aimed at preventing further tragedies involving Indian-made syrups.
Eli Lilly has paused its obesity awareness campaign in India after the country’s drug regulator cautioned it over potential rule violations. The initiative sought to reframe obesity as a chronic disease using multiple media formats without naming specific products. Lilly says regulatory uncertainty and conflicting guidance led to the halt, while the regulator warned against indirect promotion of medicines.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
India’s drug regulator is starting a major overhaul by planning to recruit more than 1,500 scientists and technology specialists. The move is designed to streamline drug approval processes and bring them closer to international benchmarks. Officials say the expanded expertise will strengthen pharmaceutical governance and help the regulator work faster and more consistently as the sector evolves.
India’s drug regulator, the Central Drugs Standard Control Organisation, has transferred about 95 officials across states as part of a structured policy. The stated goal is to strengthen compliance in the pharmaceutical sector and reduce the influence of long-serving officers. Officials say the reshuffle is intended to refresh oversight and improve how rules are enforced nationwide.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
